Heron Therapeutics, Inc. has announced a significant change in its business direction by entering into an asset purchase agreement with CorMedix Inc. This agreement, finalized on November 8, 2026, involves the sale of substantially all of Heron's assets, excluding certain tax attributes. The transaction is poised to reshape Heron's operational landscape and highlights ongoing consolidation trends within the pharmaceutical preparations industry.

The agreement includes a combination of cash and stock considerations, totaling approximately $145 million in cash, along with the issuance of 14,583,333 shares of CorMedix common stock. Additionally, Heron will receive royalties based on future sales of its products, including CINVANTI® and SUSTOL®. This strategic move reflects Heron's efforts to streamline its operations and focus on core competencies.

Background

Heron Therapeutics, Inc. is a Delaware-based company specializing in pharmaceutical preparations, as classified under SIC 2834. The company trades on the Nasdaq under the ticker HRTX. Recent filings indicate a series of transactions and corporate actions leading up to this asset sale, including multiple 8-K filings and Form 4 submissions in November 2026.

What the Filing Says

The asset purchase agreement stipulates that CorMedix will acquire most of Heron’s assets while assuming certain liabilities. The filing details that Heron will retain its federal income tax net operating loss carryforwards and certain other tax attributes. The agreement outlines various financial arrangements, including royalties and earn-out payments based on future sales performance.

Impact

This transaction may significantly affect Heron’s operational focus and financial structure. By divesting a substantial portion of its assets, Heron aims to enhance its financial position and streamline its business model. For CorMedix, the acquisition represents an opportunity to expand its product portfolio and market presence in the pharmaceutical sector.

What's Next

The filing does not specify what happens next following this agreement. However, it is expected that both companies will proceed with the necessary regulatory approvals and finalize the transaction details as outlined in the purchase agreement.